{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:28:27Z","timestamp":1791052107287,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.vaccine.2013.10.081","type":"journal-article","created":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T21:31:00Z","timestamp":1393968660000},"page":"1595-1601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["HPV vaccines to prevent cervical cancer and genital warts: an update"],"prefix":"10.1016","volume":"32","author":[{"given":"Carine","family":"Dochez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes J.","family":"Bogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Verhelst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.10.081_bib0005","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30 Suppl 5","author":"Forman","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0010","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1016\/j.ejca.2009.07.018","article-title":"Trends of cervical cancer mortality in the member states of the European Union","volume":"45","author":"Arbyn","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0015","series-title":"The epidemiology of human papillomavirus and cervical cancer","first-page":"251","article-title":"HPV and cervical neoplasia: review of case-control and cohort studies","author":"Munoz","year":"1992"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/(SICI)1096-9896(199703)181:3<253::AID-PATH755>3.0.CO;2-0","article-title":"Do HPV-negative cervical carcinomas exist","volume":"181","author":"Walboomers","year":"1997","journal-title":"J Pathol"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0025","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1016\/j.vaccine.2008.05.064","article-title":"Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia","volume":"26 Suppl 10","author":"Bosch","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2013.10.081_bib0030","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1073\/pnas.80.2.560","article-title":"zur Hausen H Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers","volume":"80","author":"Gissmann","year":"1983","journal-title":"PNAS"},{"issue":"5","key":"10.1016\/j.vaccine.2013.10.081_bib0035","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1086\/590560","article-title":"Human papillomavirus genotype distribution in external acuminata condylomata: a large French National Study (EDiTH IV)","volume":"47","author":"Aubin","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2013.10.081_bib0040","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2013.10.081_bib0045","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1086\/522863","article-title":"The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries","volume":"196","author":"Kjaer","year":"2007","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2013.10.081_bib0050","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/sextrans-2012-050512","article-title":"Genital warts in men: a large population-based cross-sectional survey of Danish men","volume":"88","author":"Munk","year":"2012","journal-title":"Sex Transm Infect"},{"issue":"9296","key":"10.1016\/j.vaccine.2013.10.081_bib0055","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(01)06886-6","article-title":"Sexual behaviour in Britain: reported sexually transmitted infections and prevalent genital Chlamydia trachomatis infection","volume":"358","author":"Fenton","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2013.10.081_bib0060","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/OLQ.0b013e3181632d61","article-title":"Genital warts among 18- to 59-year-olds in the United States: national health and nutrition examination survey, 1999\u20132004","volume":"35","author":"Dinh","year":"2008","journal-title":"Sex Transm Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2013.10.081_bib0065","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1467-842X.2003.tb00813.x","article-title":"Sex in Australia: knowledge about sexually transmissible infections and blood-borne viruses in a representative sample of adults","volume":"27","author":"Grulich","year":"2003","journal-title":"Aust NZ J Public Health"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0070","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.virol.2013.04.023","article-title":"Cross-roads in the classification of papillomaviruses","volume":"445","author":"de Villiers","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0075","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(05)67069-9","article-title":"Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis","volume":"366","author":"Clifford","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0080","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/cncr.22751","article-title":"Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing","volume":"111","author":"Schiffman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0085","doi-asserted-by":"crossref","first-page":"F168","DOI":"10.1016\/j.vaccine.2012.06.045","article-title":"Human papillomavirus, human immunodeficienty virus and immunosuppression","volume":"30S","author":"Denny","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0090","doi-asserted-by":"crossref","first-page":"F83","DOI":"10.1016\/j.vaccine.2012.04.106","article-title":"Human papillomavirus vaccines\u2014immune responses","volume":"30 Suppl 5","author":"Stanley","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0095","doi-asserted-by":"crossref","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomaviruses","volume":"30 Suppl 5","author":"Doorbar","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1743-422X-7-11","article-title":"Mechanisms of cell entry by human papillomaviruses: an overview","volume":"7","author":"Horvath","year":"2010","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0105","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/CEJ.0b013e32833720de","article-title":"Stromal issues in cervical cancer: a review of the role and function of basement membrane, stroma, immune response and angiogenesis in cervical cancer development","volume":"19","author":"Sahebali","year":"2010","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0110","first-page":"118","volume":"vol. 84 (15)","author":"World Health Organization","year":"2009"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0115","series-title":"The immunological basis for immunization series. Module 19: human papillomavirus infection","author":"World Health Organization","year":"2011"},{"issue":"2","key":"10.1016\/j.vaccine.2013.10.081_bib0120","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4161\/hv.7.2.13690","article-title":"Long-term protection against cervical cancer infection with the human papillomavirus","volume":"7","author":"Romanowski","year":"2011","journal-title":"Hum Vaccines"},{"issue":"5","key":"10.1016\/j.vaccine.2013.10.081_bib0125","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1542\/peds.2006-0461","article-title":"Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6: 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women","volume":"118","author":"Block","year":"2006","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.vaccine.2013.10.081_bib0130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jadohealth.2008.10.002","article-title":"Immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in healthy boys aged 10\u201318 years","volume":"44","author":"Petaja","year":"2009","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0135","doi-asserted-by":"crossref","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"On behalf of FUTURE I\/II Study Group. Four years efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomized controlled trial","volume":"341","author":"Dillner","year":"2010","journal-title":"BMJ"},{"issue":"9686","key":"10.1016\/j.vaccine.2013.10.081_bib0140","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 ASO4-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2013.10.081_bib0145","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2159-8290.CD-11-0131","article-title":"Prevention of persistent human papillomavirus infection by an HPV16\/18 vaccine: a community-based randomised clinical trial in Guanacaste, Costa Rica","volume":"1","author":"Herrero","year":"2011","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0150","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30S","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0155","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.vaccine.2013.10.081_bib0160","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4161\/hv.18865","article-title":"Sustained immunogenicity and efficacy of the HPV-16\/18 ASO4-adjuvanted vaccine","volume":"8","author":"Roteli-Martins","year":"2012","journal-title":"Hum Vaccines Immunother"},{"issue":"19","key":"10.1016\/j.vaccine.2013.10.081_bib0165","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2013.10.081_bib0170","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Mu\u00f1oz","year":"2010","journal-title":"J Nat Cancer Inst"},{"issue":"7","key":"10.1016\/j.vaccine.2013.10.081_bib0175","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/sti.2009.037788","article-title":"Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women","volume":"85","author":"Fairley","year":"2009","journal-title":"Sex Transm Infect"},{"issue":"7","key":"10.1016\/j.vaccine.2013.10.081_bib0180","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/sextrans-2011-050234","article-title":"The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme","volume":"87","author":"Read","year":"2011","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0185","doi-asserted-by":"crossref","first-page":"f2032","DOI":"10.1136\/bmj.f2032","article-title":"Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data","volume":"346","author":"Ali","year":"2013","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vaccine.2013.10.081_bib0190","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/OLQ.0b013e31827bd66b","article-title":"Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program","volume":"40","author":"Baandrup","year":"2013","journal-title":"Sex Transm Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2013.10.081_bib0195","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/infdis\/jis405","article-title":"Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability","volume":"206","author":"Leval","year":"2012","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2013.10.081_bib0200","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/jnci\/djt032","article-title":"Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study","volume":"105","author":"Leval","year":"2013","journal-title":"J Nat Cancer Inst"},{"issue":"5","key":"10.1016\/j.vaccine.2013.10.081_bib0205","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2105\/AJPH.2011.300465","article-title":"Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007\u20132010","volume":"102","author":"Bauer","year":"2012","journal-title":"Am J Public Health"},{"issue":"50","key":"10.1016\/j.vaccine.2013.10.081_bib0210","first-page":"7","article-title":"Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies","volume":"10","author":"Harper","year":"2010","journal-title":"Discovery Med"},{"issue":"10","key":"10.1016\/j.vaccine.2013.10.081_bib0215","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18\u201345 years","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum Vaccines"},{"issue":"12","key":"10.1016\/j.vaccine.2013.10.081_bib0220","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4161\/hv.7.12.18281","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 vaccine and HPV-6\/11\/16\/18 vaccine: follow-up from months 12\u201324 in a phase III randomised study of healthy women aged 18\u201345 years","volume":"7","author":"Einstein","year":"2011","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0225","doi-asserted-by":"crossref","first-page":"S334","DOI":"10.1016\/S0020-7292(12)60641-9","article-title":"On behalf of the HPV-010 Study Group. Comparison of immunogenicity of two prophylactic human papillomavirus (HPV) vaccines as month 48","volume":"119S3","author":"Einstein","year":"2012","journal-title":"Int J Gynecol Obstetrics"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0230","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VPL vaccine formulated with the MPL\/aluminium salt combination (ASO4) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.vaccine.2013.10.081_bib0235","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine","volume":"25","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2013.10.081_bib0240","first-page":"465","article-title":"AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix(R)): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types","volume":"71","author":"McKeage","year":"2011","journal-title":"Drugs"},{"issue":"Supp 3","key":"10.1016\/j.vaccine.2013.10.081_bib0245","doi-asserted-by":"crossref","first-page":"S323","DOI":"10.1016\/S0020-7292(12)60610-9","article-title":"Safety and immunogenicity of the HPV-16\/18 ASO4-adjuvanted vaccine in HIV-positive women in South Africa up to 12 months after vaccination","volume":"119","author":"Denny","year":"2012","journal-title":"Int J Gynecol Obstetrics"},{"issue":"2","key":"10.1016\/j.vaccine.2013.10.081_bib0250","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0b013e3181de8d26","article-title":"Safety and immunogenicity of a quadrivalent human papillomavirus (types 6: 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old","volume":"55","author":"Levin","year":"2010","journal-title":"J Acquir Immun Defic Syndr"},{"issue":"11","key":"10.1016\/j.vaccine.2013.10.081_bib0255","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.vaccine.2011.01.001","article-title":"HPV16\/18 L1 VLP vaccine induces cross-neutralising antibodies that may mediate cross-protection","volume":"29","author":"Kemp","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0260","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","author":"Malagon","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2013.10.081_bib0265","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.4161\/hv.7.12.18282","article-title":"Comparison of the immunogenicty of the human papillomavirus (HPV)-16\/18 vaccine and the HPV-6\/11\/16\/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years","volume":"7","author":"Einstein","year":"2011","journal-title":"Hum Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2013.10.081_bib0270","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV16\/18 ASO4 adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomized, double blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0275","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2249.2010.04268.x","article-title":"Monitoring of human papillomavirus vaccination","volume":"163","author":"Dillner","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0280","doi-asserted-by":"crossref","DOI":"10.1093\/aje\/kwt018","article-title":"Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination","author":"Tota","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0285","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2011-3587","article-title":"Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction","author":"Kahn","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J Nat Cancer Inst"},{"issue":"12","key":"10.1016\/j.vaccine.2013.10.081_bib0295","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4161\/hv.7.12.18322","article-title":"Immunogenicity and safety of the HPV-16\/18 ASO4-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule. Results from a randomized study","volume":"7","author":"Romanowski","year":"2011","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0300","doi-asserted-by":"crossref","first-page":"S476","DOI":"10.1016\/S0020-7292(12)61038-8","article-title":"Immune response to the HPV-16\/18 ASO4-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 3 years after vaccination","volume":"119S3","author":"Schwarz","year":"2012","journal-title":"Int J Gynecol Obstetrics"},{"issue":"17","key":"10.1016\/j.vaccine.2013.10.081_bib0305","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs. 3 doses in young women","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0310","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-7-38","article-title":"Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease","volume":"7","author":"Serrano","year":"2012","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0315","unstructured":"V503, ClinicalTrials search result."},{"key":"10.1016\/j.vaccine.2013.10.081_bib0320","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/icb.2009.13","article-title":"Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection","volume":"87","author":"Karanam","year":"2009","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0325","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1016\/j.vaccine.2013.07.052","article-title":"A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants","volume":"31","author":"Tumban","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0330","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.vaccine.2012.03.009","article-title":"Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb\/c mice","volume":"30","author":"Yoon","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0335","doi-asserted-by":"crossref","first-page":"e23310","DOI":"10.1371\/journal.pone.0023310","article-title":"A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2","volume":"6","author":"Tumban","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0340","doi-asserted-by":"crossref","first-page":"F71","DOI":"10.1016\/j.vaccine.2012.05.091","article-title":"Therapy of human papillomavirus-related disease","volume":"30","author":"Stern","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0345","doi-asserted-by":"crossref","first-page":"C28","DOI":"10.1016\/j.vaccine.2012.03.032","article-title":"Introducing human papillomavirus vaccines into the health system in South Africa","volume":"30S","author":"Botha","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0350","doi-asserted-by":"crossref","first-page":"F139","DOI":"10.1016\/j.vaccine.2012.05.039","article-title":"Human papillomavirus vaccine introduction\u2014the first five years","volume":"30S","author":"Markowitz","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0355","doi-asserted-by":"crossref","first-page":"a769","DOI":"10.1136\/bmj.a769","article-title":"Economic evaluation of human papillomavirus vaccination in the United Kingdom","volume":"337","author":"Jit","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0360","doi-asserted-by":"crossref","first-page":"F157","DOI":"10.1016\/j.vaccine.2012.06.091","article-title":"Modeling preventative strategies against human papillomvirus-related disease in developed countries","volume":"30S","author":"Canfell","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0365","doi-asserted-by":"crossref","unstructured":"Bogaards JA, Kretzschmar M, Xiridou M, Meijer CJLM, Berkhof J, Wallinga J. Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models. PLoS Med 8(12):e1001147. http:\/\/dx.doi.org\/10.1371\/journal.pmed.1001147.","DOI":"10.1371\/journal.pmed.1001147"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0370","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2407-13-10","article-title":"Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe","volume":"13","author":"Marty","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0375","unstructured":"Australian Government. Department of health and aging. \u3008http:\/\/www.health.gov.au\/internet\/immunise\/publishing.nsf\/Content\/immunise-hpv\u3009 [cited 11 June 2013]."},{"key":"10.1016\/j.vaccine.2013.10.081_bib0380","unstructured":"Department of Health. Annual HPV vaccine coverage in England in 2009\/2010. \u3008https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/147510\/dh_123826.pdf\u3009 [cited 11 June 2013]."},{"key":"10.1016\/j.vaccine.2013.10.081_bib0385","unstructured":"Top G, Paeps A. HPV vaccinatie in Vlaanderen \u2013 resultaten van het eerste vaccinatiejaar 2010\u20132011. Infectieziektebulletin http:\/\/www.infectieziektebulletin.be\/defaultSubsite.aspx?id=31494# [cited 12 June 2013]."},{"issue":"29","key":"10.1016\/j.vaccine.2013.10.081_bib0390","first-page":"591","article-title":"Human papillomavirus vaccination coverage among adolescent girls, 2007\u20132012, and postlicensure vaccine safety monitoring, 2006\u20132013\u2014United States","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMRW"},{"issue":"9777","key":"10.1016\/j.vaccine.2013.10.081_bib0395","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/S0140-6736(11)60622-3","article-title":"Financing HPV vaccination in developing countries","volume":"377","author":"Editorial","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0400","unstructured":"GAVI Alliance. http:\/\/www.gavialliance.org\/library\/news\/press-releases\/2013\/hpv-price-announcement\/ [cited 11 June 2013]."},{"key":"10.1016\/j.vaccine.2013.10.081_bib0405","doi-asserted-by":"crossref","first-page":"B81","DOI":"10.1016\/j.vaccine.2012.11.085","article-title":"Global support for new vaccine implementation in middle-income countries","volume":"31S","author":"Kaddar","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.081_bib0410","series-title":"Vaccine prices","author":"PAHO Revolving Fund","year":"2013"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13014886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13014886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:50:58Z","timestamp":1565225458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13014886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":82,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0264410X13014886"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.10.081","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718316024.793532222","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HPV vaccines to prevent cervical cancer and genital warts: an update","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.10.081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}